Haematology 2018

First page Table of contents Previous page 913 Next page Last page

The paradigm for study design….don’t change practice yet

R-CHOP

Biological and clinical stratification

R

DLBCL

R-CHOP+X

Ongoing X= Lenalidomide Ibrutinib Bortezomib Brentuximab Everolimus Tazemetostat More to come…

Can we practically deliver this design in phase III with so many agents?

Made with FlippingBook - professional solution for displaying marketing and sales documents online